NASDAQ:MLND - Millendo Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$14.69 +0.25 (+1.73 %)
(As of 03/24/2019 04:00 PM ET)
Previous Close$14.69
Today's Range$14.10 - $14.84
52-Week Range$6.77 - $15.15
Volume25,014 shs
Average Volume26,841 shs
Market Capitalization$189.65 million
P/E Ratio-0.74
Dividend YieldN/A
Beta3.3
Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome. The company is based in Ann Arbor, Michigan.

Receive MLND News and Ratings via Email

Sign-up to receive the latest news and ratings for MLND and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MLND
CUSIPN/A
CIKN/A
Phone617-500-2802

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$290,000.00
Book Value$27.00 per share

Profitability

Net Income$-50,970,000.00
Net Margins-10,128.37%

Miscellaneous

Employees22
Market Cap$189.65 million
Next Earnings DateN/A
OptionableNot Optionable

Millendo Therapeutics (NASDAQ:MLND) Frequently Asked Questions

What is Millendo Therapeutics' stock symbol?

Millendo Therapeutics trades on the NASDAQ under the ticker symbol "MLND."

What price target have analysts set for MLND?

3 analysts have issued 12 month price objectives for Millendo Therapeutics' shares. Their predictions range from $22.00 to $29.00. On average, they expect Millendo Therapeutics' stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 70.2% from the stock's current price. View Analyst Price Targets for Millendo Therapeutics.

What is the consensus analysts' recommendation for Millendo Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Millendo Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Millendo Therapeutics.

Has Millendo Therapeutics been receiving favorable news coverage?

Press coverage about MLND stock has been trending neutral recently, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Millendo Therapeutics earned a daily sentiment score of 0.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an effect on the company's share price in the immediate future.

Who are some of Millendo Therapeutics' key competitors?

What other stocks do shareholders of Millendo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Millendo Therapeutics investors own include AbbVie (ABBV), General Electric (GE), Micron Technology (MU), Constellation Brands (STZ), Mid-America Apartment Communities (MAA), Randgold Resources (GOLD), Pfizer (PFE), United States Steel (X), Colgate-Palmolive (CL) and Lendlease Group (LLC).

Who are Millendo Therapeutics' key executives?

Millendo Therapeutics' management team includes the folowing people:
  • Dr. Julia C. Owens Ph.D., Chief Exec. Officer, Pres and Director (Age 46)
  • Dr. Gary Hammer M.D., Ph.D., Co-Founder and Chairman of Scientific Advisory Board
  • Mr. Louis J. Arcudi III, MBA, Chief Financial Officer (Age 58)
  • Mr. Jeffery M. Brinza J.D., Chief Admin. Officer, Gen. Counsel & Sec. (Age 57)
  • Dr. Pharis Mohideen, Chief Medical Officer (Age 54)

Who are Millendo Therapeutics' major shareholders?

Millendo Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Frazier Management LLC (10.82%), Great Point Partners LLC (9.98%), Adams Street Partners LLC (3.56%), Prosight Management LP (1.99%), Worth Venture Partners LLC (0.20%) and BlackRock Inc. (0.20%).

Which major investors are buying Millendo Therapeutics stock?

MLND stock was purchased by a variety of institutional investors in the last quarter, including Frazier Management LLC, Great Point Partners LLC, Adams Street Partners LLC, Prosight Management LP, Worth Venture Partners LLC, BlackRock Inc., Geode Capital Management LLC and Geode Capital Management LLC.

How do I buy shares of Millendo Therapeutics?

Shares of MLND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Millendo Therapeutics' stock price today?

One share of MLND stock can currently be purchased for approximately $14.69.

How big of a company is Millendo Therapeutics?

Millendo Therapeutics has a market capitalization of $189.65 million and generates $290,000.00 in revenue each year. The company earns $-50,970,000.00 in net income (profit) each year or ($19.79) on an earnings per share basis. Millendo Therapeutics employs 22 workers across the globe.

What is Millendo Therapeutics' official website?

The official website for Millendo Therapeutics is http://www.ovascience.com.

How can I contact Millendo Therapeutics?

Millendo Therapeutics' mailing address is 9 FOURTH AVENUE, WALTHAM MA, 02451. The company can be reached via phone at 617-500-2802 or via email at [email protected]


MarketBeat Community Rating for Millendo Therapeutics (NASDAQ MLND)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  22 (Vote Outperform)
Underperform Votes:  29 (Vote Underperform)
Total Votes:  51
MarketBeat's community ratings are surveys of what our community members think about Millendo Therapeutics and other stocks. Vote "Outperform" if you believe MLND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MLND will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel